Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0132 Phase 3 Long-term Study in Dry Eye Disease
jRCT2031220392Phase 3Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of motsugibatorep in dry eye syndrome (DED), sponsored by Senju Pharmaceutical Co., Ltd. Primary endpoint: Safety. Started Jan 2023; status: completed.
02
Drugs
motsugibatorep
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on jRCT2031220392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220392.